Explore JAMA Network Open’s Immunology collection, including open access science about the causes, diagnosis, and management of immune-mediated disease.
This study of 100 randomized clinical trials determines how frequently immune checkpoint inhibitor (ICI) and non-ICI anticancer agents displayed trends of long-term durable survival as defined by the American Society of Clinical Oncology (ASCO) Value Framework and the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale.
This meta-analysis examines whether differences in biomarkers, such as programmed cell death ligand 1 (PD-L1) expression and tumor mutation burden, are associated with improved response to immunotherapy and survival in patients with advanced non–small cell lung cancer (NSCLC).
This cohort study investigates the association between tonsillectomy and renal outcomes in patients with IgA nephropathy in Japan.
This cohort study describes 2 models for predicting the long-term response to ustekinumab therapy among patients with active Crohn disease.
This economic evaluation uses a simulation to calculate the cost-effectiveness of epicutaneous peanut immunotherapy and peanut oral immunotherapy under differing assumptions.
This cohort study examines the association of occupational exposure to pesticides with immunochemotherapy response and survival in patients in France treated for diffuse large B-cell lymphoma (DLBCL).
This survival and cost-effectiveness analysis study uses survival curves from the ZUMA-1 trial (Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma) to estimate long-term survival and cost-effectiveness associated with axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, vs chemotherapy for treatment of relapsed or refractory B-cell lymphoma in adults.
This cost-effectiveness analysis uses a decision analytic model to extrapolate trial evidence to estimate the long-term survival and value of tisagenlecleucel for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
This cohort study examines the association of screening for hypogammaglobulinemia with the risk of infection and mortality in patients who received rituximab therapy.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: